ArticleOncoTargets and therapy2016
miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 59 citations in OpenAlex.
- IGFBP1 is One of 10 Metabolic Factors Predicting Recurrence Free Survival in Gastric Cancer and Promotes Cancer Progression via ZFX-IGFBP1 Axis.OncoTargets and therapy · 2025Article
- Recent Insights into the Angioregulatory Role of Long Non-coding RNAs and Circular RNAs in Gliomas: From Signaling Pathways to Clinical Aspects.Current medicinal chemistry · 2025Review
- Identification the Tumor Mechanics-Related Biomarkers in Gastric Cancer Patients Based on Bioinformatics and Machine Learning.International journal of general medicine · 2025Article
- Dual-regulatory miRNAs: master regulators and therapeutic targets in bone-metastatic breast cancer.Frontiers in molecular biosciences · 2025Review
- Circ_0008035 Promotes Gastric Cancer Development via the miR-429/SMAD2 Cascade.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- RUNX1/miR-429 feedback loop promotes growth, metastasis, and epithelial-mesenchymal transition in oral squamous cell carcinoma by targeting ITGB1.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- PCAT19: the role in cancer pathogenesis and beyond.Frontiers in cell and developmental biology · 2024Review
- Hsa_circ_0084912 Drives the Progression of Cervical Cancer Via Regulating miR-429/SOX2 Pathway.Molecular biotechnology · 2023Article
- Exosomal MicroRNA Analyses in Esophageal Squamous Cell Carcinoma Cell Lines.Journal of clinical medicine · 2022Article
- Immunomodulatory Properties of Human Breast Milk: MicroRNA Contents and Potential Epigenetic Effects.Biomedicines · 2022Review
- Article
- The role of miR-200 family in the regulation of hallmarks of cancer.Frontiers in oncology · 2022Review
- Identification of circRNA Biomarker for Gastric Cancer through Integrated Analysis.Frontiers in molecular biosciences · 2022Article
- The decreased expression of miR-429 in plasma exosomes after spinal cord injury inhibits neuronal apoptosis by mediating the PTEN/PI3K/Akt pathway.Annals of translational medicine · 2022Article
- HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis.Digestive diseases and sciences · 2021Article
- hsa‑miR‑429 targets CBX8 to promote cell apoptosis in diffuse large B‑cell lymphoma.Molecular medicine reports · 2021Article
- Integrative analysis of the gastric cancer long non-coding RNA-associated competing endogenous RNA network.Oncology letters · 2021Article
- Emerging Role of Fascin-1 in the Pathogenesis, Diagnosis, and Treatment of the Gastrointestinal Cancers.Cancers · 2021Review
- Article
- The microRNA-429/DUSP4 axis regulates the sensitivity of colorectal cancer cells to nintedanib.Molecular medicine reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been previously reported that the deregulation of microRNAs in gastric cancer (GC) was correlated with the progression and prognosis. miR-429, a member of the miR-200 family, was previously shown to play an important role in human carcinomas. Our study shows that miR-429 is significantly downregulated in GC tissues compared with matched nontumor tissues. Overexpression of miR-429 in GC cells suppressed cell proliferation. Fascin-1 (FSCN1) was identified as one of the targets of miR-429 and knockdown of FSCN1 mimics the function of miR-429 overexpression. In conclusion, miR-429 acts as a tumor suppressor by targeting FSCN1, suggesting that miR-429 and FSCN1 can both be potential therapeutic targets of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.